Victoria Weston PhD
About Victoria Weston PhD
Victoria Weston, PhD, is a Medical Scientist specializing in Cell Therapy at Kite Pharma, with extensive experience in cancer research and immuno-oncology biomarkers. She has held various academic and industry positions, focusing on drug resistance mechanisms and novel therapies for leukemia.
Work at Kite Pharma
Victoria Weston has been employed at Kite Pharma, a Gilead Company, as a Medical Scientist in Cell Therapy within the Medical Affairs department since 2019. In this role, she contributes to the development and implementation of cell therapy strategies, focusing on advancing treatment options for patients. Her expertise in competitive intelligence and immuno-oncology biomarkers plays a crucial role in her current responsibilities.
Education and Expertise
Victoria Weston earned her Bachelor of Science (BSc) with Honors in Genetics from the University of Wales, Cardiff, from 1994 to 1998. She furthered her education at The University of Birmingham, where she completed her Doctor of Philosophy (PhD) in the School of Medicine and Dentistry between 1998 and 2002. Her academic background supports her expertise in competitive intelligence and immuno-oncology biomarkers.
Background
Victoria Weston has extensive experience in cancer research and medical affairs. She worked as a Post-Doctoral Research Fellow at the University of Birmingham from 2002 to 2005 and later as a Senior Post-Doctoral Research Fellow from 2010 to 2014, both in the School of Cancer Sciences. Additionally, she served as an LLR Programme Grant Post-Doctoral Research Fellow from 2006 to 2010, focusing on molecular mechanisms of drug resistance and relapse in cancer.
Previous Roles in Oncology
Before her current role at Kite Pharma, Victoria Weston worked as a Medical Science Manager in Haemato-Oncology at Otsuka Pharmaceutical in collaboration with Bristol-Myers Squibb and Astex Pharmaceuticals from 2014 to 2018. In this position, she was involved in developing novel therapies for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic lymphocytic leukemia (CLL).